英語ページ

Publications 2022

  1. Akamatsu, S., Terada, N., Takata, R., Kinoshita, H., Shimatani, K., Momozawa, Y., Yamamoto, M., Tada, H., Kawamorita, N., Narita, S., Kato, T., Nitta, M., Kandori, S., Koike, Y., Inazawa, J., Kimura, T., Kimura, H., Kojima, T., Terachi, T., Sugimoto, M., Habuchi, T., Arai, Y., Yamamoto, S., Matsuda, T., Obara, W., Kamoto, T., Inoue, T., Nakagawa, H., Ogawa, O.(2022) Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy. JNCI. Cancer Spectr., 6, pkac001.
  2. Furukawa, J., Hinata, N., Teisima, J., Takenaka, A., Shiroki, R., Kobayashi, Y., Kanayama, HO., Hattori, K., Horie, S., Tozawa, K., Kato, M., Ohyama C., Habuchi, T., Kawamorita, N., Eto, M., Fujisawa, M.(2022) Robot-assisted partial nephrectomy with minimum follow-up of 5 years: A multi-center prospective study in Japan. Int. J. Urol., 29, 1038-1045.
  3. Inoue, T., Miyake, M., Nishimura, N., Onozawa, M., Kashima, S., Numakura, K., Narita, S., Iida, K., Uemura, M., Matsushita, Y., Inokuchi, J., Matsui, Y., Taoka, R., Kojima, T., Kobayashi, T., Nishiyama, N., Kitamura, H., Nishiyama, H., Fujimoto, K., Habuchi, T. (2022) Association of increased age with decreased response to intravesical instillation of bacille calmette-guérin in patients with high-risk non-muscle invasive bladder cancer: retrospective multi-institute results from the Japanese urological oncology research group JUOG-UC-1901-BCG. Urology, 167,158-164.
  4. Iwamura, H., Mizuno, K., Akamatsu, S., Hatakeyama, S., Tobisawa, Y., Narita, S., Narita, T., Yamashita, S., Kawamura, S., Sakurai, T., Fujita, N., Kodama, H., Noro, D., Kakizaki, I., Nakaji, S., Itoh, K., Tsuchiya, N., Ito, A., Habuchi, T., Ohyama, C., Yoneyama, T. (2022) Machine learning diagnosis by immunoglobulin N-glycan signatures for precision diagnosis of urological diseases. Cancer Sci., 113, 2434-2445.
  5. Kimura, H., Mizuno, K., Shiota, M., Narita, S., Terada, N., Fujimoto, N., Ogura, K., Hatano, S., Iwasaki, Y., Hakozaki, N., Ishitoya, S., Sumiyoshi, T., Goto, T., Kobayashi, T., Nakagawa, H., Kamoto, T., Eto, M., Habuchi, T., Ogawa, O., Momozawa, Y., Akamatsu, S. (2022) Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer. Br J. Cancer, 127, 1680-1690.
  6. Kanda, S., Inoue, T., Nakajima, S., Sagehashi, R., Nara, T., Numakura, K., Saito, M., Narita, S., Tsuchiya, N., Habuchi, T. (2022) Comparison of parenchymal volume loss assessed by three-dimensional computed tomography volumetry and renal functional recovery between conventional and robot-assisted laparoscopic partial nephrectomy. Asian J. Endosc. Surg., 15, 63-69.
  7. Kato, R., Naito, S., Numakura, K., Hatakeyama, S., Koguchi, T., Kojima, T., Kawasaki, Y., Kandori, S., Kawamura, S., Arai, Y., Ito, A., Nishiyama, H., Kojima, Y., Ohyama, C., Habuchi, T., Tsuchiya, N., Obara, W. (2022) Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study. Int. J. Clin. Oncol., 27, 563-573.
  8. Kobayashi, M., Fujiyama, N., Tanegashima, T., Narita, S., Yamamoto, Y., Fujimoto, N., Ueda, S., Takeuchi, A., Numakura, K., Habuchi, T., Matsuyama, H., Eto, M., Shiota, M. (2022) Effect of HLA genotype on intravesical recurrence after bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer. Cancer Immunol Immunother. 71, 727-736.
  9. Kobayashi, M., Narita, S., Matsui, Y., Kanda, S., Hidaka, Y., Abe, H., Tsuzuki, T., Ito, K., Kojima, T., Kato, M., Hatakeyama, S., Matsushita, Y., Naito, S., Shiga, M., Miyake, M., Muro, Y., Nakanishi, S., Kato, Y., Shibuya, T., Hayashi, T., Yasumoto, H., Yoshida, T., Uemura, M., Taoka, R., Kamiyama, M., Morita, S., Habuchi, T., Ogawa, O., Nishiyama, H., Kitamura, H., Kobayashi, T. (2022) Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis. BJU. Int., 130, 226-234.
  10. Kobayashi, M., Numakura, K., Hatakeyama, S., Muto, Y., Sekine, Y., Sasagawa, H., Kashima, S., Yamamoto, R., Koizumi, A., Nara, T., Saito, M., Narita, S., Ohyama, C., Habuchi, T. (2022) Severe immune-related adverse events in patients treated with nivolumab for metastatic renal cell carcinoma are associated with PDCD1 polymorphism. Genes (Basel), 13, 1204.
  11. Lee, YH., Sato, Y., Saito, M., Fukuma, S., Saito, M., Yamamoto, S., Komatsuda, A., Fujiyama, N., Satoh, S., Lee, SH., Boor, P., Habuchi, T., Floege, J., Yanagita, M. (2022) Advanced tertiary lymphoid tissues in protocol biopsies are associated with progressive graft dysfunction in kidney transplant recipients. J. Am. Soc. Nephrol., 33, 186-200.
  12. Miura, Y., Hatakeyama, S., Narita, S., Kimura, T., Hata, K., Yanagisawa, T., Tanaka, T., Ishi, N., Kawamura, S., Hoshi, S., Ishidoya, S., Mitsuzuka, K., Ito, A., Tsuchiya, N., Egawa, S., Habuchi, T., Ohyama, C. (2022) Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration-sensitive prostate cancer: A multicenter retrospective study. Prostate, 82, 1304-1312.
  13. Morozumi, K., Mitsuzuka, K., Narita, S., Takahashi, M., Kawamura, S., Tochigi, T., Arai, Y., Hoshi, S., Shimoda, J., Ishidoya, S., Okamoto, T., Hatakeyama, S., Sakurai, T., Tsuchiya, N., Ohyama, C., Habuchi, T., Ito, A. (2022) Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone-sensitive prostate cancer with Gleason score ≥8. Int. J. Urol., 29, 324-331.
  14. Narita, S., Terada, N., Nomura, K., Sakamoto, S., Hatakeyama, S., Kato, T., Matsui, Y., Inokuchi, J., Yokomizo, A., Tabata, KI., Shiota, M., Kimura, T., Kojima, T., Inoue, T., Mizowaki, T., Sugimoto, M., Kitamura, H., Kamoto, T., Nishiyama, H., Habuchi, T. (2022) Cancer-specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy. Int. J. Urol., 29, 1147-1154.
  15. Narita, S., Kimura, T., Hatakeyama, S., Hata, K., Yanagisawa, T., Maita, S., Chiba, S., Sato, H., Kashima, S., Koizumi, A., Yamamoto, R., Takayama, K., Okane, K., Ishida, T., Horikawa, Y., Kumazawa, T., Shimoda, J., Suzuki, T., Ohyama, C., Egawa, S., Habuchi, T. (2022) Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel. Int. J. Clin. Oncol., 27, 1477-1486.
  16. Narita, S., Hatakeyama, S., Sakamoto, S., Kato, T., Inokuchi, J., Matsui, Y., Kitamura, H., Nishiyama, H., Habuchi, T. (2022) Management of prostate cancer in older patients. Jpn. J. Clin. Oncol., 52, 513-525.
  17. Narita, S., Kimura, T., Hatakeyama, S., Hata, K., Yanagisawa, T., Maita, S., Chiba, S., Sato, H., Kashima, S., Koizumi, A., Yamamoto, R., Takayama, K., Okane, K., Ishida, T., Horikawa, Y., Kumazawa, T., Shimoda, J., Suzuki, T., Ohyama. C., Egawa. S., Nomura. K., Habuchi, T. (2022) Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy. World J. Urol., 40, 1135-1141.
  18. Numakura, K., Kobayashi, M., Ishida, T., Okane, K., Suzuki, K., Shimoda, N., Suzuki, T., Kumazawa, T., Sasaki, R., Fukuda, H., Kashima, S., Yamamoto, R., Koizumi, A., Nara, T., Kanda, S., Huang, M., Saito, M., Narita, S., Inoue, T., Tsuchiya, N., Habuchi, T. (2022) Effect of levofloxacin on the efficacy and adverse events in intravesical bacillus calmette-guerin treatment for bladder cancer: results of a randomized, prospective, multicenter study. Eur. Urol. Focus, 8, 1666-1672.
  19. Numakura, K., Kobayashi, M., Koizumi, A., Kashima, S., Yamamoto, R., Nara, T., Saito. M., Narita, S., Inoue, T., Habuchi, T.(2022) Factors influencing warm ischemia time in robot-assisted partial nephrectomy change depending on the surgeon's experience. World J. Surg. Oncol., 20, 202.
  20. Sato, H., Narita, S., Ishida, M., Takahashi, Y., Mingguo, H., Kashima, S., Yamamoto, R., Koizumi, A., Nara, T., Numakura, K., Saito, M., Yoshioka, T., Habuchi, T. (2022) Specific gut microbial environment in lard diet-induced prostate cancer development and progression. Int. J. Mol. Sci., 23, 2214.
  21. Sekine, Y., Iwasaki, Y., Hakozaki, N., Endo, M., Kamatani, Y., Matsuda, K., Murakami, Y., Sano, T., Akamatsu, S., Kobayashi, T., Nakagawa, H., Numakura, K., Narita, S., Habuchi, T., Momozawa, Y.(2022) Prevalence and risk estimation of cancer-predisposing genes for upper urinary tract urothelial carcinoma in Japanese. Jpn J. Clin. Oncol., 52, 1441-1445.
  22. Sekine, Y., Iwasaki, Y., Aoi, T., Endo, M., Hirata, M., Kamatani, Y., Matsuda, K., Sugano, K., Yoshida, T., Murakami, Y., Fukui, T., Akamatsu, S., Ogawa, O., Nakagawa, H., Numakura, K., Narita, S., Habuchi, T., Momozawa, Y. (2022) Different risk genes contribute to clear cell and non-clear cell renal cell carcinoma in 1532 Japanese patients and 5996 controls. Hum Mol Genet. 31, 1962-1969.
  23. Takahashi, S., Narita, S., Fujiyama, N., Hatakeyama, S., Kobayashi, T., Kato, R., Naito, S., Sakatani, T., Kashima, S., Koizumi, A., Yamamoto, R., Nara, T., Kanda, S., Numakura, K., Saito, M., Obara, W., Tsuchiya, N., Ohyama, C., Ogawa, O., Habuchi, T.(2022) Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab. Cancer Sci., 113, 4059-4069.
  24. Takayama, K., Numakura, K., Igarashi, R., Habuchi, T. (2022) Complete remission of brain metastases in renal cell carcinoma treated with axitinib after failure with nivolumab and ipilimumab treatment. IJU Case Rep., 5, 517-520.
  25. Yagishita, H., Kagaya, H., Saito, M., Numakura, K., Yamamoto, R., Sagehashi, R., Habuchi, T., Satoh, S., Miura, M. (2022) Effects of NR1I2 and ABCB1 genetic polymorphisms on everolimus pharmacokinetics in Japanese renal transplant patients. Int. J. Mol. Sci., 23, 11742.
  26. Yanagisawa, T., Kimura, T., Hata, K., Narita, S., Hatakeyama, S., Enei, Y., Atsuta, M., Mori, K., Obayashi, K., Yoshihara, K., Kondo, Y., Oguchi, T., Sadakane, I., Habuchi, T., Ohyama, C., Shariat, SF., Egawa, S.(2022) Does castration status affect docetaxel-related adverse events? Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer. Prostate, 82, 1322-1330.
  27. Yanagisawa, T., Kimura, T., Hata, K., Narita, S., Hatakeyama, S., Mori, K., Sano, T., Otsuka, T., Iwamoto, Y., Enei, Y., Nakazono, M., Sakanaka, K., Iwatani, K., Matsukawa, A., Atsuta, M., Nishikawa, H., Tsuzuki, S., Miki, J., Habuchi, T., Ohyama, C., Shariat, SF., Egawa, S. (2022) Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis. World J. Urol., 10, 1007.
  28. Takahashi, Y., Narita, S., Shiota, M., Miura, M., Kagaya, H., Kashima, S., Yamamoto, R., Nara, T., Huang, M., Numakura, K., Saito, M., Eto, M., Habuchi, T. (2022) Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate. Eur. J. Clin., Pharmacol. 79, 89-98.
  29. Numakura, K., Nakai, Y., Kojima, T., Osawa, T., Narita, S., Nakayama, M., Kitamura, H., Nishiyama, H., Shinohara, N.(2022)Overview of clinical management for older patients with renal cell carcinoma. Jpn. J. Clin. Oncol., 52, 665-681.
  30. Tamura, D., Narita, S., Yamauchi, M., Watanabe, R., Yokoyama, S., Kikuchi, A., Shitara, A., Chiba, S., Saito, F., Sugita, A., Sato, K., Karube, A.(2022) Perinatal Management in a Pregnant Woman with Ureteropelvic Junction Obstruction: Case Report and Literature Review. Diagnostics (Basel), 12, 913.
  31. Shiota, M., Takamatsu, D., Kimura, T., Tashiro, K., Matsui, Y., Tomida, R., Saito, R., Tsutsumi, M., Yokomizo, A., Yamamoto, Y., Edamura, K., Miyake, M., Morizane, S., Yoshino, T., Matsukawa, A., Narita, S., Matsumoto, R., Kasahara, T., Hashimoto, K., Matsumoto, H., Kato, M., Akamatsu, S., Joraku, A., Kato, M., Yamaguchi, T., Saito, T., Kaneko, T., Takahashi, A., Kato, T., Sakamoto, S., Enokida, H., Kanno, H., Terada, N., Suekane, S., Nishiyama, N., Eto, M., Kitamura, H.(2022)Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancer. Cancer Sci., 113, 2386-2396.
  32. Terada, N., Sawada, A., Kawanishi, H., Fujimoto, T., Magaribuchi, T., Chihara, I., Hashimoto, K., Sakurai, T., Shimizu, Y., Uegaki, M., Nakashima, M., Narita, S., Kubota, M., Yamada, Y., Tohi, Y., Okabe, K., Yatsuda, J., Kamoto, T. (2022) The efficacy of sequential therapy with docetaxel and cabazitaxel for castration-resistant prostate cancer: A retrospective multi-institutional study in Japan. Int. J. Urol., 30, 227-234.
  33. Ozaki, K., Hatakeyama, S., Narita, S., Hata, K., Yanagisawa, T., Tanaka, T., Togashi, K., Hamaya, T., Okamoto, T., Yamamoto, H., Yoneyama, T., Hashimoto, Y., Kimura, T., Habuchi, T., Ohyama, C.(2022)Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study. World J. Urol., 41, 67-75.
  34. Powles, T., Tomczak, P., Park, SH., Venugopal, B., Ferguson, T., Symeonides, SN., Hajek, J., Gurney, H., Chang, YH., Lee, JL., Sarwar, N., Thiery-Vuillemin, A., Gross-Goupil, M., Mahave, M., Haas, NB., Sawrycki, P., Burgents, JE., Xu, L., Imai, K., Quinn, DI., Choueiri, TK; KEYNOTE-564 Investigators. (2022)Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol., 23, 1133-1144.
  35. Nishimura, N., Miyake, M., Iida, K., Miyamoto, T., Tomida, R., Numakura, K., Inokuchi, J., Yoneyama, T., Matsumura, Y., Yajima, S., Masuda, H., Terada, N., Taoka, R., Kobayashi, T., Kojima, T., Matsui, Y., Nishiyama, N., Kitamura, H., Nishiyama, H., Fujimoto, K. (2022) Prognostication in Japanese patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy. Int J Urol., 29, 242-249.
  36. Takeda, M., Kashima, S., Fuchigami, Y., Yoshino, T., Kataoka, TR., Yamasaki, T., Kagamu, H., Kobayashi, T., Akamatsu, S. (2022) A Case of Renal Cell Carcinoma Unclassified with Medullary Phenotype Exhibiting a Favorable Response to Combined Immune Checkpoint Blockade., Front Immunol. 5, 934991.
  37. Hagimoto, H., Sano, T., Kashima, S., Yoshino, T., Goto, T., Sawada, A., Akamatsu, S., Yamasaki, T., Fujimoto, M., Kajita, Y., Kobayashi, T., Ogawa, O. (2022) Rapidly Progressive Bladder Cancer Diagnosed because of Spontaneous Bladder Rupture. Case Rep. Urol., 9, 1-7.

メニューを開く